TD Asset Management Inc Boosts Stock Holdings in Amgen Inc. $AMGN

TD Asset Management Inc grew its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 3.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 420,259 shares of the medical research company’s stock after buying an additional 15,810 shares during the quarter. TD Asset Management Inc owned 0.08% of Amgen worth $152,184,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Vanguard Group Inc. increased its stake in Amgen by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after purchasing an additional 961,975 shares during the period. State Street Corp boosted its stake in shares of Amgen by 4.4% during the fourth quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock valued at $10,012,872,000 after purchasing an additional 1,287,310 shares during the period. Capital World Investors grew its holdings in shares of Amgen by 22.9% in the fourth quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after purchasing an additional 4,302,237 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Amgen by 7.8% in the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after purchasing an additional 1,035,779 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of Amgen in the fourth quarter worth $2,164,162,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analyst Ratings Changes

AMGN has been the subject of a number of recent analyst reports. Canaccord Genuity Group upped their price target on shares of Amgen from $366.00 to $384.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. UBS Group boosted their price objective on shares of Amgen from $420.00 to $440.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Erste Group Bank restated a “hold” rating on shares of Amgen in a research report on Tuesday, May 5th. Piper Sandler reaffirmed an “overweight” rating on shares of Amgen in a research note on Friday, June 12th. Finally, Daiwa Securities Group dropped their target price on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a report on Wednesday, May 13th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, fifteen have issued a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $372.39.

Insider Activity

In other Amgen news, SVP Nancy A. Grygiel sold 2,970 shares of the firm’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the sale, the senior vice president directly owned 7,340 shares in the company, valued at $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Rachna Khosla sold 1,252 shares of Amgen stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the sale, the senior vice president directly owned 6,404 shares in the company, valued at approximately $2,666,817.72. The trade was a 16.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 6,222 shares of company stock valued at $2,540,926 over the last 90 days. 0.85% of the stock is currently owned by company insiders.

Amgen Stock Performance

NASDAQ:AMGN opened at $415.21 on Friday. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The firm’s fifty day simple moving average is $370.57 and its 200 day simple moving average is $358.93. The stock has a market cap of $224.47 billion, a P/E ratio of 25.81, a price-to-earnings-growth ratio of 3.86 and a beta of 0.41. Amgen Inc. has a twelve month low of $269.77 and a twelve month high of $421.79.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping the consensus estimate of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. During the same period in the prior year, the business earned $6.02 EPS. The company’s revenue for the quarter was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, research analysts predict that Amgen Inc. will post 22.78 EPS for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Friday, August 21st. Amgen’s dividend payout ratio is presently 62.65%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.